General autoimmunity

Oral

Unaffected Relatives of Systemic Lupus Erythematosus (sle) Patients Are Discerned by Soluble Mediators, Autoantibodies, and Connective Tissue Disease Questionnaire Scores from Sle Patients and Controls in a Confirmatory Cohort

Thursday, June 15
5:45 PM - 7:00 PM

Identifying populations at risk of SLE is essential to curtail inflammatory damage and implement prevention strategies. Using unique participant resources, this study examined an initial cohort of previously unaffected blood relatives who transitioned to classified SLE (n=45), plus a confirmatory cohort of European-American (EA) (n=50) and African-American (AA) (n=50) SLE patients, matched by race and gender to unaffected relatives (n=190) and unrelated healthy controls (Ctls, n=145). Participants provided clinical and demographic information, and completed the SLE-specific portion of the CTD Screening Questionnaire (SLE-CSQ). Plasma samples were assessed for autoantibody production and for 52 soluble mediators by multiplexed bead-based assays or ELISA. In both cohorts, compared to unaffected relatives, Ctls had significantly lower (p=0.001), while SLE patients had significantly higher (p0.001), SLE-CSQ scores. Irrespective of race, a strong correlation existed between SLE-CSQ scores, number of ACR criteria, and number of autoantibody specificities (p0.001). A strong correlation was noted between these three aforementioned variables and select soluble mediators, including TNF superfamily member BLyS, pro-inflammatory mediator stem cell factor (SCF), and the regulatory mediator IL-10 (p≤0.004 for each mediator), among others. Levels of BLyS in unaffected relatives and Ctls were significantly lower than SLE patients (p0.001). Unaffected relatives had intermediate levels of SCF between SLE patients (p≤0.01) and Ctls (p≤0.03). In contrast, unaffected relatives had significantly higher levels of the regulatory mediator IL-10 than SLE patients (p0.001). Identification of factors which discern unaffected lupus relatives from SLE patients may be beneficial to identify potential treatments to curtail inflammatory damage for prevention trials.

Melissa E. Munroe

Oklahoma Medical Research Foundation

Presentation(s):

    Send Email for Melissa Munroe

    Kendra A. Young

    Colorado School of Public Health

    Presentation(s):

      Send Email for Kendra Young

      Teresa Aberle

      Oklahoma Medical Research Foundation

      Presentation(s):

        Send Email for Teresa Aberle

        Virginia C. Roberts

        Oklahoma Medical Research Foundation

        Presentation(s):

          Send Email for Virginia Roberts

          Joel M. Guthridge

          Oklahoma Medical Research Foundation

          Presentation(s):

            Send Email for Joel Guthridge

            Diane L. Kamen

            Medical University of South Carolina

            Presentation(s):

              Send Email for Diane Kamen

              Gary S. Gilkeson

              Medical University of South Carolina

              Presentation(s):

                Send Email for Gary Gilkeson

                Michael H. Weisman

                Cedars-Sinai Medical Center

                Presentation(s):

                  Send Email for Michael Weisman

                  Mariko L. Ishimori

                  Cedars-Sinai Medical Center

                  Presentation(s):

                    Send Email for Mariko Ishimori

                    Daniel J. Wallace

                    Cedars-Sinai Medical Center

                    Presentation(s):

                      Send Email for Daniel Wallace

                      David R. Karp

                      University of Texas Southwestern Medical Center

                      Presentation(s):

                        Send Email for David Karp

                        Kathy L. Sivils

                        Oklahoma Medical Research Foundation

                        Presentation(s):

                          Send Email for Kathy Sivils

                          John B. Harley

                          Cincinnati Children’s Hospital Medical Center and US Department of Veterans Affairs Medical Center

                          Presentation(s):

                            Send Email for John Harley

                            Jill M. Norris

                            Colorado School of Public Health

                            Presentation(s):

                              Send Email for Jill Norris

                              Judith A. James

                              Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center

                              Presentation(s):

                                Send Email for Judith James


                                Assets

                                Unaffected Relatives of Systemic Lupus Erythematosus (sle) Patients Are Discerned by Soluble Mediators, Autoantibodies, and Connective Tissue Disease Questionnaire Scores from Sle Patients and Controls in a Confirmatory Cohort



                                Attendees who have favorited this

                                Send Email for Unaffected Relatives of Systemic Lupus Erythematosus (sle) Patients Are Discerned by Soluble Mediators, Autoantibodies, and Connective Tissue Disease Questionnaire Scores from Sle Patients and Controls in a Confirmatory Cohort